{"doc_id": "si-2021-0718-reg-1", "parent_doc_id": "si-2021-0718", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 718 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "1. (1) These Regulations may be cited as the Medicinal Products", "text_raw": "1. (1) These Regulations may be cited as the Medicinal Products \n(Prescription and Control of Supply) (Amendment) (No. 15) Regulations 2021. \n\n(2) The collective citation “the Medicinal Products (Prescription and Control \n\nof Supply) Regulations 2003 to 2021” includes these Regulations.", "text_norm": "1 (1) regulation may cited medicinal product (prescription control supply) (amendment) (no 15) regulation 2021 (2) collective citation medicinal product (prescription control supply) regulation 2003 2021 includes regulation", "start_char": 626, "end_char": 916, "source_path": "downloads\\2021\\2021_0718.pdf", "extraction_method": "pdfminer", "checksum": "sha256:fd94cb8d750a3bfd02c70927073e5ebf28fc5534451fb777b6c4f3d82907239f", "cross_refs": []}
{"doc_id": "si-2021-0718-reg-2", "parent_doc_id": "si-2021-0718", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 718 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Principal Regulations” means the Medicinal Products (Prescription and Control \nof Supply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“Regulations of 2021” means the Medicinal Products (Prescription and Control \nof Supply) (Amendment) (No. 14) Regulations 2021 (S.I. No. 692 of 2021).", "text_norm": "2 regulations-- principal regulation mean medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) regulation 2021 mean medicinal product (prescription control supply) (amendment) (no 14) regulation 2021 (s.i no 692 2021)", "start_char": 916, "end_char": 1232, "source_path": "downloads\\2021\\2021_0718.pdf", "extraction_method": "pdfminer", "checksum": "sha256:fd94cb8d750a3bfd02c70927073e5ebf28fc5534451fb777b6c4f3d82907239f", "cross_refs": []}
{"doc_id": "si-2021-0718-reg-3", "parent_doc_id": "si-2021-0718", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 718 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of", "text_raw": "3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of \n\n2021) to the Principal Regulations is amended— \n\n(a) by substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty concentrate for dispersion for \ninjection COVID-19 mRNA Vaccine (nucleoside modified)” the \nfollowing: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics— \n\n(a) \n\nan additional dose may be administered \nto \nimmunocompromised persons who are 12 years of \nage or older and have already received a primary \nvaccine course against Covid-19, and \n\n(b) \n\na booster dose may be administered to— \n\n(i) \n\n(ii) \n\npersons who are 16 years of age or older and \nhave already received a primary vaccine course \nagainst Covid-19, and \n\nimmunocompromised persons who are 12 years \nof age or older and have already received an \nadditional dose of a Covid-19 vaccine, \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 31st December, 2021. \n\n \n \n \n \n \n \n \n\f[718] 3 \n\nin such volumes, at such intervals, in such manner and in such \norder of prioritisation (whether by reference to age, employment \nsector, pregnancy or otherwise), as may be specified in such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”, \n\n(b) by substituting for the text in column 5 of the entry for the \nmedicinal product “Spikevax (previously Covid-19 Vaccine \nModerna) dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics— \n\n(a) \n\nan additional dose may be administered \nto \nimmunocompromised persons who are 30 years of \nage or older and have already received a primary \nvaccine course against Covid-19, and \n\n(b) \n\na booster dose may be administered to— \n\n(i) \n\n(ii) \n\npersons who are 30 years of age or older and \nhave already received a primary vaccine course \nagainst Covid-19, and \n\nimmunocompromised persons who are 30 years \nof age or older and have already received an \nadditional dose of a Covid-19 vaccine, \n\nin such volumes, at such intervals, in such manner and in such \norder of prioritisation (whether by reference to age, employment \nsector, pregnancy or otherwise), as may be specified in such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”, and \n\n(c) by inserting the following additional entry— \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nRoute of \nadministrati\non \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministrati\non \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nColumn 6 \n\nComirnaty 10 \nmicrograms/do\nse concentrate \nfor dispersion \nfor injection \n\nConcentrate \nfor dispersion \nfor injection \n(sterile \nconcentrate) \n\nComirnaty is \nadministered \nintra \nmuscularly \nafter dilution. \n\nIndicated for \nactive \nimmunisatio\nn to prevent \nCOVID-19 \n\nIn accordance with \nrelevant \nrecommendations \nor guidelines \nissued by the \n\nAny suitable \nand \nappropriate \nplace, having \nregard to \npublic \n\n \n\f4 [718] \n\nMedicinal \nproduct \n\nCOVID-19 \nmRNA \n\nVaccine \n(nucleoside \nmodified) \nPaediatric \npack \n\nForm and \npresentation \nof the \nproduct \nadministered \n\nRoute of \nadministrati\non \n\nin a multidose \nvial that must \nbe diluted \nbefore use. \n\nOne dose \n(0.2 mL) \ncontains 10 \n\nmicrograms \nof \ntozinamera\nn, a COVID19 mRNA \nVaccine \n(embedded \nin lipid \nnanoparticl\nes). \n\nIndication \nfor which \nthe \nmedicinal \nproduct \nmay be \nadminister\ned \n\ncaused by \nSARSCoV-2 \nvirus, in \nindividual\ns aged 5 \nto 11 \nyears at \nthe time \nof their \nfirst dose. \n\nDosage and \nconditions of \nadministration \n\nPlace of \nadministrati\non \n\nconvenience \nand the need \nto protect the \nhealth and \nsafety of the \npublic and \nsafely \nadminister \nthe product. \n\nNational \nImmunisation \nAdvisory \nCommittee and \naccepted by the \nMinister for Health, \nsubject to \ninformed consent \nbeing obtained \nfrom a parent or \nguardian. \n\nAdministered as a \ncourse of 2 doses \n(0.2 mL each) at \nleast 19 days \napart. \n\nAn additional \ndose should be \nadministered to \nchildren aged 5 to \n11 years who are \nseverely \nimmunocomprom\nised at least 28 \ndays after the \nsecond dose to \ncomplete the \nprimary series. \n\nThe additional dose \nshould be \nadministered in \nsuch manner and \norder of \nprioritisation \n(whether by \nreference to age, \nimmune status, \nliving \narrangements or \notherwise), as may \nbe specified in such \nrecommendations \nor guidelines. \n\n”. \n\n \n \n \n \n \n \n \n\f[718] 5", "text_norm": "3 eighth schedule (as amended regulation 3 regulation 2021) principal regulation amended-- (a) substituting text column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristics-- (a) additional dose may administered immunocompromised person 12 year age older already received primary vaccine course covid-19 (b) booster dose may administered to-- (i) (ii) person 16 year age older already received primary vaccine course covid-19 immunocompromised person 12 year age older already received additional dose covid-19 vaccine notice making statutory instrument published iris oifigiuil 31st december 2021 718 3 volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained (b) substituting text column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristics-- (a) additional dose may administered immunocompromised person 30 year age older already received primary vaccine course covid-19 (b) booster dose may administered to-- (i) (ii) person 30 year age older already received primary vaccine course covid-19 immunocompromised person 30 year age older already received additional dose covid-19 vaccine volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained (c) inserting following additional entry-- medicinal product form presentation product administered route administrati indication medicinal product may administer ed dosage condition administration place administrati column 1 column 2 column 3 column 4 column 5 column 6 comirnaty 10 microgram se concentrate dispersion injection concentrate dispersion injection (sterile concentrate) comirnaty administered intra muscularly dilution indicated active immunisatio n prevent covid-19 accordance relevant recommendation guideline issued suitable appropriate place regard public 4 718 medicinal product covid-19 mrna vaccine (nucleoside modified) paediatric pack form presentation product administered route administrati multidose vial must diluted use one dose (0.2 ml) contains 10 microgram tozinamera n covid19 mrna vaccine (embedded lipid nanoparticl es) indication medicinal product may administer ed caused sarscov-2 virus individual aged 5 11 year time first dose dosage condition administration place administrati convenience need protect health safety public safely administer product national immunisation advisory committee accepted minister health subject informed consent obtained parent guardian administered course 2 dos (0.2 ml each) least 19 day apart additional dose administered child aged 5 11 year severely immunocomprom ised least 28 day second dose complete primary series additional dose administered manner order prioritisation (whether reference age immune status living arrangement otherwise) may specified recommendation guideline  718 5", "start_char": 1232, "end_char": 6197, "source_path": "downloads\\2021\\2021_0718.pdf", "extraction_method": "pdfminer", "checksum": "sha256:fd94cb8d750a3bfd02c70927073e5ebf28fc5534451fb777b6c4f3d82907239f", "cross_refs": []}
{"doc_id": "si-2021-0718-reg-4", "parent_doc_id": "si-2021-0718", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 718 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations", "text_raw": "4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations \n\n2021) to the Principal Regulations is amended— \n\n(a) by substituting for the text in column 5 of the entry for the \nmedicinal product “Comirnaty concentrate for dispersion for \ninjection COVID-19 mRNA Vaccine (nucleoside modified)” the \nfollowing: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct chaacteristics— \n\n(a) \n\nan additional dose may be administered \nto \nimmunocompromised persons who are 12 years of \nage or older and have already received a primary \nvaccine course against Covid-19, and \n\n(b) \n\na booster dose may be administered to— \n\n(i) \n\n(ii) \n\npersons who are 16 years of age or older and \nhave already received a primary vaccine course \nagainst Covid-19, and \n\nimmunocompromised persons who are 12 years \nof age or older and have already received an \nadditional dose of a Covid-19 vaccine, \n\nin such volumes, at such intervals, in such manner and in such \norder of prioritisation (whether by reference to age, employment \nsector, pregnancy or otherwise), as may be specified in such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”, \n\n(b) by substituting for the text in column 5 of the entry for the \nmedicinal product “Spikevax (previously Covid-19 Vaccine \nModerna) dispersion for injection COVID-19 mRNA Vaccine \n(nucleoside modified)” the following: \n\n“In accordance with relevant recommendations or guidelines \nissued by the National Immunisation Advisory Committee and \naccepted by the Minister for Health. \n\nNotwithstanding any directions to the contrary in the summary of \nproduct characteristics— \n\n(a) \n\nan additional dose may be administered \nto \nimmunocompromised persons who are 30 years of \nage or older and have already received a primary \nvaccine course against Covid-19, and \n\n(b) \n\na booster dose may be administered to— \n\n(i) \n\npersons who are 30 years of age or older and \nhave already received a primary vaccine course \nagainst Covid-19, and \n\n \n\f6 [718] \n\n(ii) \n\nimmunocompromised persons who are 30 years \nof age or older and have already received an \nadditional dose of a Covid-19 vaccine, \n\nin such volumes, at such intervals, in such manner and in such \norder of prioritisation (whether by reference to age, employment \nsector, pregnancy or otherwise), as may be specified in such \nrecommendations or guidelines, and subject to informed consent \nbeing obtained.”, and \n\n(c) by inserting the following additional entry — \n\n“ \n\nMedicinal \nproduct \n\nForm and \npresentation of \nthe product \nadministered \n\nRoute of \nadministration \n\nIndication for \nwhich the \nmedicinal \nproduct may \nbe \nadministered \n\nDosage and conditions of \nadministration \n\nColumn 1 \n\nColumn 2 \n\nColumn 3 \n\nColumn 4 \n\nColumn 5 \n\nComirnaty is \nadministered \nintramuscularly \nafter dilution. \n\nIndicated for \nactive \nimmunisation \nto prevent \nCOVID-19 \n\ncaused by \nSARS-CoV-2 \nvirus, in \nindividuals \naged 5 to 11 \nyears at the \ntime of their \nfirst dose. \n\nComirnaty \n10 \nmicrograms/ \n\ndose \nconcentrate \nfor \ndispersion \nfor injection \nCOVID-19 \nmRNA \n\nVaccine \n(nucleoside \nmodified) \nPaediatric \npack \n\nConcentrate \nfor dispersion \nfor injection \n(sterile \nconcentrate) \nin a multidose \nvial that must \nbe diluted \nbefore use. \n\nOne dose (0.2 \nmL) contains \n10 \n\nmicrograms of \ntozinameran, \na COVID-19 \nmRNA Vaccine \n(embedded in \nlipid \nnanoparticles). \n\nIn accordance with \nrelevant \nrecommendations or \nguidelines issued by the \nNational Immunisation \nAdvisory Committee and \naccepted by the Minister \nfor Health, subject to \ninformed consent being \nobtained from a parent \nor guardian. \n\nAdministered as a course \nof 2 doses (0.2 mL each) \nat least 19 days apart. \n\nAn additional dose \nshould be administered \nto children aged 5 to 11 \nyears who are severely \nimmunocompromised at \nleast 28 days after the \nsecond dose to complete \nthe primary series. \n\nThe additional dose \nshould be administered \nin such manner and \norder of prioritisation \n(whether by reference to \nage, living arrangements \nor otherwise), as may be \nspecified in such \nrecommendations or \nguidelines. \n\n \n \n \n \n \n \n\f[718] 7 \n\n”. \n\nGIVEN under the Official Seal of the Minister for Health, \n\n16 December, 2021. \n\nMUIRIS O'CONNOR, \n\nA person authorised under section 15 of the Ministers and \nSecretaries Act 1924 to authenticate the seal of the Minister \nfor Health.. \n\n \n \n \n \n \n \n \n \n \n \n \n\f8 [718]", "text_norm": "4 twelfth schedule (as amended regulation 4 regulation 2021) principal regulation amended-- (a) substituting text column 5 entry medicinal product comirnaty concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product chaacteristics-- (a) additional dose may administered immunocompromised person 12 year age older already received primary vaccine course covid-19 (b) booster dose may administered to-- (i) (ii) person 16 year age older already received primary vaccine course covid-19 immunocompromised person 12 year age older already received additional dose covid-19 vaccine volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained (b) substituting text column 5 entry medicinal product spikevax (previously covid-19 vaccine moderna) dispersion injection covid-19 mrna vaccine (nucleoside modified) following accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health notwithstanding direction contrary summary product characteristics-- (a) additional dose may administered immunocompromised person 30 year age older already received primary vaccine course covid-19 (b) booster dose may administered to-- (i) person 30 year age older already received primary vaccine course covid-19 6 718 (ii) immunocompromised person 30 year age older already received additional dose covid-19 vaccine volume interval manner order prioritisation (whether reference age employment sector pregnancy otherwise) may specified recommendation guideline subject informed consent obtained (c) inserting following additional entry -- medicinal product form presentation product administered route administration indication medicinal product may administered dosage condition administration column 1 column 2 column 3 column 4 column 5 comirnaty administered intramuscularly dilution indicated active immunisation prevent covid-19 caused sars-cov-2 virus individual aged 5 11 year time first dose comirnaty 10 microgram dose concentrate dispersion injection covid-19 mrna vaccine (nucleoside modified) paediatric pack concentrate dispersion injection (sterile concentrate) multidose vial must diluted use one dose (0.2 ml) contains 10 microgram tozinameran covid-19 mrna vaccine (embedded lipid nanoparticles) accordance relevant recommendation guideline issued national immunisation advisory committee accepted minister health subject informed consent obtained parent guardian administered course 2 dos (0.2 ml each) least 19 day apart additional dose administered child aged 5 11 year severely immunocompromised least 28 day second dose complete primary series additional dose administered manner order prioritisation (whether reference age living arrangement otherwise) may specified recommendation guideline 718 7  given official seal minister health 16 december 2021 muiris connor person authorised section 15 minister secretary act 1924 authenticate seal minister health 8 718", "start_char": 6197, "end_char": 10782, "source_path": "downloads\\2021\\2021_0718.pdf", "extraction_method": "pdfminer", "checksum": "sha256:fd94cb8d750a3bfd02c70927073e5ebf28fc5534451fb777b6c4f3d82907239f", "cross_refs": []}
{"doc_id": "si-2021-0718-explanatory-note", "parent_doc_id": "si-2021-0718", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 718 of 2021", "title": "“Principal Regulations” means the Medicinal Products (Prescription and Control", "year": 2021, "heading": "(This note is not part of the Instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the Instrument and does not purport to be a legal \ninterpretation.) \n\nThese Regulations amend the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003. \n\nThe purpose of these Regulations is to update the relevant schedules in relation \nto the COVID-19 vaccines, by taking account of the extension of the vaccination \nprogramme to include children aged 5 to 11 years being administered Comirnaty \nCOVID-19 Vaccine, Paediatric Formulation, as per NIAC recommendations of \n7 December 2021, and to provide for boosters in accordance with NIAC \nrecommendations of 13 December 2021. \n\nThese Regulations may be cited as the Medicinal Products (Prescription and \nControl of Supply) (Amendment) (No. 15) Regulations 2021. \n\n \n \n \n \n \n \n \n \n\f[718] 9 \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€3.00 \n\n(DH-353) 75. 12/21. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal interpretation.) regulation amend medicinal product (prescription control supply) regulation 2003 purpose regulation update relevant schedule relation covid-19 vaccine taking account extension vaccination programme include child aged 5 11 year administered comirnaty covid-19 vaccine paediatric formulation per niac recommendation 7 december 2021 provide booster accordance niac recommendation 13 december 2021 regulation may cited medicinal product (prescription control supply) (amendment) (no 15) regulation 2021 718 9 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur3.00 (dh-353) 75 12 21 propylon", "start_char": 10782, "end_char": 12073, "source_path": "downloads\\2021\\2021_0718.pdf", "extraction_method": "pdfminer", "checksum": "sha256:fd94cb8d750a3bfd02c70927073e5ebf28fc5534451fb777b6c4f3d82907239f", "cross_refs": []}
